145 related articles for article (PubMed ID: 10470292)
1. Contribution of the nucleoside transport system to doxorubicin transport in HL60 cells but not in mononuclear cells.
Nagasawa K; Fumihara T; Ohnishi N; Yokoyama T
Jpn J Cancer Res; 1999 Jul; 90(7):781-7. PubMed ID: 10470292
[TBL] [Abstract][Full Text] [Related]
2. Possibility of contribution of nucleoside transport systems to pirarubicin uptake by HL60 cells but not mononuclear cells.
Nagasawa K; Ohnishi N; Yokoyama T
Jpn J Cancer Res; 1998 Jun; 89(6):673-80. PubMed ID: 9703366
[TBL] [Abstract][Full Text] [Related]
3. Transport mechanisms of idarubicin, an anthracycline derivative, in human leukemia HL60 cells and mononuclear cells, and comparison with those of its analogs.
Nagasawa K; Ohnishi N; Yokoyama T
Jpn J Cancer Res; 1997 Aug; 88(8):750-9. PubMed ID: 9330607
[TBL] [Abstract][Full Text] [Related]
4. Transport mechanism of anthracycline derivatives in human leukemia cell lines: uptake and efflux of daunorubicin and doxorubicin in HL60 and its resistant cells and comparison with those of pirarubicin.
Nagasawa K; Natazuka T; Nomiyama M; Ohnishi N; Yokoyama T
Biol Pharm Bull; 1996 Jan; 19(1):100-5. PubMed ID: 8820920
[TBL] [Abstract][Full Text] [Related]
5. Comparison of uptake mechanisms for anthracyclines in human leukemic cells.
Karim H; Bogason A; Bhuiyan H; Fotoohi AK; Lafolie P; Vitols S
Curr Drug Deliv; 2013 Aug; 10(4):404-12. PubMed ID: 23062181
[TBL] [Abstract][Full Text] [Related]
6. Transport mechanism of pirarubicin in human mononuclear cells.
Nagasawa K; Tsumura A; Nomiyama M; Ohnishi N; Yokoyama T
Biol Pharm Bull; 1996 Sep; 19(9):1203-9. PubMed ID: 8889041
[TBL] [Abstract][Full Text] [Related]
7. Contribution of specific transport systems to anthracycline transport in tumor and normal cells.
Nagasawa K; Nagai K; Ohnishi N; Yokoyama T; Fujimoto S
Curr Drug Metab; 2001 Dec; 2(4):355-66. PubMed ID: 11766987
[TBL] [Abstract][Full Text] [Related]
8. Transport mechanism of anthracycline derivatives in human leukemia cell lines: uptake and efflux of pirarubicin in HL60 and pirarubicin-resistant HL60 cells.
Nagasawa K; Natazuka T; Chihara K; Kitazawa F; Tsumura A; Takara K; Nomiyama M; Ohnishi N; Yokoyama T
Cancer Chemother Pharmacol; 1996; 37(4):297-304. PubMed ID: 8548874
[TBL] [Abstract][Full Text] [Related]
9. Transport mechanisms of anthracycline derivatives in human leukemia cell lines: uptake of pirarubicin, daunorubicin and doxorubicin by K562 and multidrug-resistant K562/ADM cells.
Nagasawa K; Takara K; Nomiyama M; Ohnishi N; Yokoyama T
Biol Pharm Bull; 1996 Jul; 19(7):971-6. PubMed ID: 8839972
[TBL] [Abstract][Full Text] [Related]
10. Pirarubicin is taken up by a uridine-transportable sodium-dependent concentrative nucleoside transporter in Ehrlich ascites carcinoma cells.
Nagai K; Nagasawa K; Ishimoto A; Fujimoto S
Cancer Chemother Pharmacol; 2003 Jun; 51(6):512-8. PubMed ID: 12679883
[TBL] [Abstract][Full Text] [Related]
11. Uptake of the anthracycline pirarubicin into mouse M5076 ovarian sarcoma cells via a sodium-dependent nucleoside transport system.
Nagai K; Nagasawa K; Fujimoto S
Cancer Chemother Pharmacol; 2005 Mar; 55(3):222-30. PubMed ID: 15526202
[TBL] [Abstract][Full Text] [Related]
12. The P-glycoprotein-mediated relative decrease in cytosolic free drug concentration is similar for several anthracyclines with varying lipophilicity.
Mülder HS; Dekker H; Pinedo HM; Lankelma J
Biochem Pharmacol; 1995 Sep; 50(7):967-74. PubMed ID: 7575681
[TBL] [Abstract][Full Text] [Related]
13. Cell cycle related uptake, retention and toxicity of idarubicin, daunorubicin and doxorubicin.
Minderman H; Linssen P; Wessels J; Haanen C
Anticancer Res; 1993; 13(4):1161-5. PubMed ID: 8352539
[TBL] [Abstract][Full Text] [Related]
14. Idarubicin overcomes P-glycoprotein-related multidrug resistance: comparison with doxorubicin and daunorubicin in human multiple myeloma cell lines.
Roovers DJ; van Vliet M; Bloem AC; Lokhorst HM
Leuk Res; 1999 Jun; 23(6):539-48. PubMed ID: 10374847
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of uptake and resistance to troxacitabine, a novel deoxycytidine nucleoside analogue, in human leukemic and solid tumor cell lines.
Gourdeau H; Clarke ML; Ouellet F; Mowles D; Selner M; Richard A; Lee N; Mackey JR; Young JD; Jolivet J; Lafrenière RG; Cass CE
Cancer Res; 2001 Oct; 61(19):7217-24. PubMed ID: 11585758
[TBL] [Abstract][Full Text] [Related]
16. The role of bioreductive activation of antitumour anthracycline drugs in cytotoxic activity against sensitive and multidrug resistant leukaemia HL60 cells.
Kostrzewa-Nowak D; Bieg B; Paine MJ; Wolf CR; Tarasiuk J
Eur J Pharmacol; 2012 Jan; 674(2-3):112-25. PubMed ID: 22115891
[TBL] [Abstract][Full Text] [Related]
17. Characterization of equilibrative and concentrative Na+-dependent (cif) nucleoside transport in acute promyelocytic leukemia NB4 cells.
Roovers KI; Meckling-Gill KA
J Cell Physiol; 1996 Mar; 166(3):593-600. PubMed ID: 8600163
[TBL] [Abstract][Full Text] [Related]
18. Susceptibility of idarubicin, daunorubicin, and their C-13 alcohol metabolites to transport-mediated multidrug resistance.
Ross DD; Doyle LA; Yang W; Tong Y; Cornblatt B
Biochem Pharmacol; 1995 Nov; 50(10):1673-83. PubMed ID: 7503771
[TBL] [Abstract][Full Text] [Related]
19. Interaction of 2',2'-difluorodeoxycytidine (gemcitabine) and formycin B with the Na+-dependent and -independent nucleoside transporters of Ehrlich ascites tumor cells.
Burke T; Lee S; Ferguson PJ; Hammond JR
J Pharmacol Exp Ther; 1998 Sep; 286(3):1333-40. PubMed ID: 9732397
[TBL] [Abstract][Full Text] [Related]
20. Comparison of idarubicin and daunorubicin regarding intracellular uptake, induction of apoptosis, and resistance.
Lotfi K; Zackrisson AL; Peterson C
Cancer Lett; 2002 Apr; 178(2):141-9. PubMed ID: 11867198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]